ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
내분비 치료제 시장 규모는 향후 몇 년간 강력한 성장이 예상될 예정입니다.
당뇨병 인구 증가, 내분비 질환 유병률 증가, 호르몬 불균형에 직면한 청소년 증가, 비만률 증가 등의 요인에 기인한다고 생각됩니다.
내분비 질환의 유병률 상승은 내분비 치료제 시장의 성장을 가속하고 있습니다. 라이프 스타일의 변화, 고령화, 진단 방법의 개선 등을 들 수 있으며, 이들은 모두 이러한 질병의 인지도와 발생률의 상승으로 이어지고 있습니다.
내분비학 약물은 호르몬 수치를 조절하고, 선 기능 장애를 해결하며, 호르몬 균형을 회복함으로써 이러한 질병을 관리하고 건강상의 결과를 개선하도록 설계되었습니다.
2023년 5월 국립 의학 도서관은 미국에서 약 1,300만 명(인구의 약 4.78%)이 진단되지 않은 내분비 질환으로 고통받고 있으며, 그 중에서도 갑상선질환이 가장 많아 내분비진료소에서 치료를 받고 있는 환자의 30-40%가 이환되고 있다고 보고했습니다.
내분비 치료제 시장의 주요 기업은 투약 관리를 강화하기 위해 즉시 사용할 수 있는 바이알과 같은 혁신적인 제품의 개발을 우선하고 있습니다. 2022년 12월 영국의 제약회사인 Hikma Pharmaceuticals plc는 농도 100mcg/mL의 Ready-to-use 바이알이 들어간 레보티록신나트륨 주사제를 출시했습니다. 땀샘 기능 저하증과 점액 수종 혼수와 같은 치료에 필수적인, 정확하고 일관된 투여가 보장됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 내분비 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계 내분비 치료제 시장 : 성장률 분석
세계 내분비 치료제 시장 실적 : 규모와 성장, 2019-2024
세계 내분비 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 내분비 치료제 전체 시장 규모(TAM)
제6장 시장 세분화
세계 내분비 치료제 시장 : 적응증별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
갑상선 기능 항진증
갑상선 기능 저하증
당뇨병
다낭성 난소 증후군
성장 호르몬 질환
뇌하수체 질환
기타 적응증
세계의 내분비 치료제 시장 : 치료 영역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
당뇨병약
갑상선 호르몬 이상증의 약
인간 성장 호르몬
테스토스테론 보충 요법
기타 치료 분야
세계 내분비 치료제 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
온라인 약국
소매 약국
세계 내분비 치료제 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
외래수술센터(ASC)
기타 최종 사용자
세계 내분비 치료제 시장 : 갑상선 기능 항진증유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
항갑상선약
방사성 요오드 요법
베타 차단제
세계 내분비 치료제 시장 : 갑상선 기능 저하증 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
레보티록신계 약제
리오티로닌계 약
병용 호르몬 요법
세계 내분비 치료제 시장 : 당뇨병유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
인슐린 요법
경구 당뇨병약(OAD)
GLP-1 수용체 작용제
SGLT-2 억제제
DPP-4 억제제
세계 내분비 치료제 시장 : 다낭성 난소 증후군(PCOS)유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
경구 피임약
메트포르민
크로미펜구연산염
안티 안드로겐
세계 내분비 치료제 시장 : 성장 호르몬 질환유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
재조합 인간 성장 호르몬(rhGH)
성장 호르몬 분비 촉진제
성장 호르몬 수용체 길항제
세계 내분비 치료제 시장 : 뇌하수체 질환유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
소마토스타틴 유사체
고나도트로핀
도파민 작용제
세계 내분비 치료제 시장 : 기타 적응증 세분화(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
부신 질환
골다공증
부갑상선 질환
남성 호르몬 불균형
제7장 지역별/국가별 분석
세계 내분비 치료제 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계 내분비 치료제 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
내분비 치료제 시장 : 경쟁 구도
내분비 치료제 시장 : 기업 프로파일
Johnson & Johnson Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer Aktiengesellschaft : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis International AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
AstraZeneca plc
Abbott Laboratories
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Amgen Inc.
Novo Nordisk A/S
Biocon Limited
Boehringer Ingelheim International GmbH
Mylan NV
Sandoz International GmbH
Ipsen Pharma
Ferring Pharmaceuticals Inc.
Endocrine Pharma Private Limited
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
내분비 치료제 시장 2029 : 새로운 기회를 제공하는 국가
내분비 치료제 시장 2029 : 새로운 기회를 제공하는 부문
내분비 치료제 시장 2029 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Endocrinology drugs are pharmaceutical treatments designed to manage and regulate disorders associated with the endocrine system, which includes glands such as the thyroid, pancreas, and adrenal glands. These drugs are used to treat conditions such as diabetes, thyroid disorders, growth hormone deficiencies, and hormonal imbalances, aiming to restore normal hormonal levels and improve the overall function of the endocrine system.
The primary conditions treated with endocrinology drugs include hyperthyroidism, hypothyroidism, diabetes, polycystic ovarian syndrome, growth hormone disorders, and pituitary gland disorders, among others. Hyperthyroidism, for example, is marked by an overproduction of thyroid hormones, causing symptoms such as weight loss, rapid heartbeat, and anxiety. Key therapy areas include diabetes medications, thyroid hormone disorder treatments, human growth hormone, testosterone replacement therapy, and others. These drugs are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by a range of end users, including hospitals, ambulatory surgical centers, and more.
The endocrinology drugs market research report is one of a series of new reports from The Business Research Company that provides endocrinology drugs market statistics, including endocrinology drugs industry global market size, regional shares, competitors with an endocrinology drugs market share, detailed endocrinology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the endocrinology drugs industry. This endocrinology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The endocrinology drugs market size has grown strongly in recent years. It will grow from $33.26 billion in 2024 to $36.21 billion in 2025 at a compound annual growth rate (CAGR) of 8.86%. The growth during the historic period can be attributed to factors such as the rising global prevalence of diabetes, increased government initiatives, higher healthcare spending, a growing incidence of adrenal gland disorders, increased demand for insulin analogs, and a higher number of endocrinologists.
The endocrinology drugs market size is expected to see strong growth in the next few years. It will grow to $50.37 billion in 2029 at a compound annual growth rate (CAGR) of 8.60%. The expected growth during the forecast period can be attributed to factors such as a growing diabetic population, a higher prevalence of endocrine disorders, more adolescents facing hormonal imbalances, and increasing obesity rates. Key trends for the forecast period include advancements in technology, the adoption of advanced drug delivery systems, the integration of digital health solutions, precision medicine, and combination therapies.
The rising prevalence of endocrine diseases is driving the growth of the endocrinology drugs market. Endocrine diseases are disorders that affect the endocrine system, leading to imbalances in hormone production or regulation, which disrupt normal bodily functions. Factors contributing to the increasing prevalence of endocrine diseases include lifestyle changes, an aging population, and improvements in diagnostic methods, which have all led to greater recognition and incidence of these conditions. Endocrinology drugs are designed to manage these diseases by regulating hormone levels, addressing glandular dysfunction, and restoring hormonal balance, thus improving health outcomes. For example, in May 2023, the National Library of Medicine reported that approximately 13 million people in the U.S. (about 4.78% of the population) suffer from undiagnosed endocrine disorders, with thyroid disease being one of the most prevalent, affecting 30% to 40% of patients treated in endocrine practices. This growing prevalence of endocrine diseases is significantly driving the demand for endocrinology drugs.
Leading companies in the endocrinology drugs market are prioritizing the development of innovative products, such as ready-to-use vials, to enhance medication administration. These pre-filled and pre-dosed containers eliminate the need for reconstitution or preparation before use. For example, in December 2022, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced Levothyroxine sodium injection in ready-to-use vials with a concentration of 100 mcg/mL. This formulation is designed for immediate application, reducing the risk of preparation errors and enhancing patient safety. It ensures precise and consistent dosing, which is essential for treating conditions such as hypothyroidism and myxedema coma. Additionally, these vials improve efficiency for healthcare providers by saving time and ensuring accurate administration in urgent care scenarios.
In July 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Amolyt Pharma Inc., a France-based company specializing in therapies for rare endocrine diseases. This acquisition is aimed at strengthening AstraZeneca's portfolio in rare endocrine diseases by integrating Amolyt Pharma's innovative pipeline of late-stage therapies. This move highlights the ongoing efforts by major pharmaceutical companies to expand their capabilities and offerings in the growing market for endocrinology drugs.
Major players in the endocrinology drugs market are Johnson & Johnson Inc., Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis International AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Biocon Limited, Boehringer Ingelheim International GmbH, Mylan N.V., Sandoz International GmbH, Ipsen Pharma, Ferring Pharmaceuticals Inc., Endocrine Pharma Private Limited.
North America was the largest region in the endocrinology drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in endocrinology drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the endocrinology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The endocrinology drugs market consists of sales of insulin analogs, antithyroid drugs, and anti-diabetic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Endocrinology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on endocrinology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for endocrinology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The endocrinology drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Indication: Hyperthyroidism; Hypothyroidism; Diabetes; Polycystic Ovarian Syndrome; Growth Hormone Disorders; Pituitary Gland Disorders; Other Indications
2) By Therapy Area: Diabetes Drugs; Thyroid Hormone Disorder Drugs; Human Growth Hormone; Testosterone Replacement Therapy; Others Therapy Areas
3) By Distribution Channel: Hospital pharmacies; Online Pharmacies; Retail pharmacies
4) By End User: Hospitals; Ambulatory Surgical Centers; Others End Users
Subsegments:
1) By Hyperthyroidism: Antithyroid Medications; Radioactive Iodine Therapy; Beta Blockers
2) By Hypothyroidism: Levothyroxine-based Medications; Liothyronine-based Medications; Combination Hormonal Therapies
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Endocrinology Drugs Market Characteristics
3. Endocrinology Drugs Market Trends And Strategies
4. Endocrinology Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Endocrinology Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Endocrinology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Endocrinology Drugs Market Growth Rate Analysis
5.4. Global Endocrinology Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Endocrinology Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Endocrinology Drugs Total Addressable Market (TAM)
6. Endocrinology Drugs Market Segmentation
6.1. Global Endocrinology Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hyperthyroidism
Hypothyroidism
Diabetes
Polycystic Ovarian Syndrome
Growth Hormone Disorders
Pituitary Gland Disorders
Other Indications
6.2. Global Endocrinology Drugs Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diabetes Drugs
Thyroid Hormone Disorder Drugs
Human Growth Hormone
Testosterone Replacement Therapy
Other Therapy Areas
6.3. Global Endocrinology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital pharmacies
Online Pharmacies
Retail pharmacies
6.4. Global Endocrinology Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Ambulatory Surgical Centers
Other End Users
6.5. Global Endocrinology Drugs Market, Sub-Segmentation Of Hyperthyroidism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antithyroid Medications
Radioactive Iodine Therapy
Beta Blockers
6.6. Global Endocrinology Drugs Market, Sub-Segmentation Of Hypothyroidism, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Levothyroxine-based Medications
Liothyronine-based Medications
Combination Hormonal Therapies
6.7. Global Endocrinology Drugs Market, Sub-Segmentation Of Diabetes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Insulin Therapies
Oral Antidiabetic Drugs (OADs)
GLP-1 Receptor Agonists
SGLT-2 Inhibitors
DPP-4 Inhibitors
6.8. Global Endocrinology Drugs Market, Sub-Segmentation Of Polycystic Ovarian Syndrome (PCOS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Contraceptives
Metformin
Clomiphene Citrate
Anti-Androgens
6.9. Global Endocrinology Drugs Market, Sub-Segmentation Of Growth Hormone Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Human Growth Hormone (rhGH)
Growth Hormone Secretagogues
Growth Hormone Receptor Antagonists
6.10. Global Endocrinology Drugs Market, Sub-Segmentation Of Pituitary Gland Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Somatostatin Analogs
Gonadotropins
Dopamine Agonists
6.11. Global Endocrinology Drugs Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adrenal Gland Disorders
Osteoporosis
Parathyroid Disorders
Male Hormonal Imbalances
7. Endocrinology Drugs Market Regional And Country Analysis
7.1. Global Endocrinology Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Endocrinology Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
